Genzyme Recovery Is Taking Off, Termeer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Ahead of an important investor meeting in New York on Friday, Genzyme reported third quarter sales showing signs that drug supply constraints are improving.
You may also be interested in...
Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Sanofi/Genzyme Saga: War Before Peace?
Unless a white knight bidder emerges to thwart Sanofi-Aventis' attempt to acquire Genzyme, and soon, the Cambridge-Mass.-based biotech's best negotiating tactic may be stalling.